NCT06620354View on ClinicalTrials.gov

Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions

Neurofibromatosis 1

Interventions

DRUG

Selumetinib

Patients without indications for surgical excision were evaluated with 6 cycles of daily oral smetinib capsules (20-50mg bid) for 30 days, individually calculated based on patient body surface area (BSA)

All Listed Sponsors

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT06620354 - Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule | Biotech Hunter | Biotech Hunter